A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Items 301–400 of 535
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks
Axelrod, M. J., Gordon, V. L., Mendez, R. E., Leimgruber, S., Conaway, M. R., Sharlow, E. R., Jameson, M. J., Gioeli, D. G., & Weber, M. J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.013 · Cited by 11
“These signaling networks have emergent properties associated with robust systems [18,19], raising the possibility that they contain critical nodes within the system, whose inhibition would lead to system collapse.”
Existence of Inverted Profile in Chemically Responsive Molecular Pathways in the Zebrafish Liver
Ung, C. Y., Lam, S. H., Zhang, X., Li, H., Ma, J., Zhang, L., Li, B., & Gong, Z. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027819 · Cited by 11
“Formulation using drug cocktails such as ‘‘long-tail drugs’’ [54] that aim to target a wide spectrum of gene activities can be the future trend in therapeutic design to modulate diverse biological processes.”
BackgroundLiu, Q., Chen, C., Gao, A., Tong, H., & Xie, L. (2017) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2017.8217995 · Cited by 11
“Our rationale is that the potential drug target should maximally reduce the robustness of the AD subnetwork [37].”
The Distribution of Mutational Effects on Fitness in a Simple Circadian Clock
Loewe, L., & Hillston, J. E. (2008) · Lecture notes in computer science · doi:10.1007/978-3-540-88562-7_14 · Cited by 11
“robustness. Understanding robustness [5] is important for drug design [ 6 ].”
BackgroundIntegrative workflows for network analysis
Khan, F. M., Gupta, S. K., & Wolkenhauer, O. (2018) · Essays in Biochemistry · doi:10.1042/ebc20180005 · Cited by 10
Systems Biology Through the Concept of Emergence
Kolodkin, A. N. (2016) · History, philosophy and theory of the life sciences · doi:10.1007/978-3-319-47000-9_17 · Cited by 10
Xi, Y., Miao, Y., Zhou, R., Wang, M., Zhang, F., Li, Y., Zhang, Y., Yang, H., & Guo, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826535 · Cited by 10
“Health systems are generally robust against drug attacks, but the disease network can be fragile facing with perturbations (Kitano, 2007).”
BackgroundNetwork modelling of gene regulation
Ho, J. W. K., & Charleston, M. (2010) · Biophysical Reviews · doi:10.1007/s12551-010-0041-4 · Cited by 11
“Instead of viewing the complex network from the lens of individual molecules, systems biologists seek to study collective properties of molecules, such as system stability, robustness, and evolvability (Huang 2004; Kitano 2007b).”
BackgroundBeyond clinical phenotype: The biologic integratome
Grimaldi, D., Claessens, Y.-É., Mira, J. P., & Chiche, J. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181920cca · Cited by 10
“Clearly, optimizing therapeutic approaches to human disease will require the application of network pharmacology (58, 59) to identify new drug targets (45), to determine the appropriate dosing of a drug based on metabolomic profiling (60), and to investigate the causes of resistance to therapies or enhanced toxicities…”
BackgroundOmer, A., & Singh, P. C. (2016) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2016.1188417 · Cited by 10
“Network biology can be a good approach to utilize single target or drug for multiple purposes (Kitano, 2007).”
BackgroundShen, P., Shen, J., Sun, C., Yang, X., & Li-qun, H. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1268-9 · Cited by 10
Singh, P. K., & Silakari, O. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102083-8.00001-7 · Cited by 10
Xu, M. Q., Zhang, L., Li, P., Wang, C., & Shi, Y. (2020) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2020.04.002 · Cited by 10
Workman, P., & Collins, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00001-2 · Cited by 10
Li, L., Zhang, N., & Li, S. (2010) · Chinese Science Bulletin · doi:10.1007/s11434-010-4067-6 · Cited by 10
Adaptive Control Model Reveals Systematic Feedback and Key Molecules in Metabolic Pathway Regulation
Quo, C. F., Moffitt, A. B., Merrill, A. H., & Wang, M. D. (2011) · Journal of Computational Biology · doi:10.1089/cmb.2010.0215 · Cited by 10
Overcoming drug resistance through in silico prediction
Carbonell, P., & Trosset, J. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.012 · Cited by 10
Systems Pharmacology: An Overview
Birtwistle, M. R., Hansen, J., Gallo, J. M., Muppirisetty, S., Ung, P. M. U., Iyengar, R., & Schlessinger, A. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_4 · Cited by 10
Curiosity-driven AI for Science : Automated Discovery of Self-Organized Structures
Etcheverry, M. (2023) · theses.fr (ABES) · doi:10.70675/5041450bz7b8az4fcez966azf89b0a4e7e48 · Cited by 10
Zhang, X., Gu, J., Cao, L., Ma, Y., Su, Z.-Z., Luo, F., Wang, Z., Li, N., Yuan, G., Chen, L., et al. (2014) · Integrative Biology · doi:10.1039/c4ib00141a · Cited by 9
Carbon-based nanoparticles and dendrimers for delivery of combination drugs
Ranch, K. M., Shukla, M. R., Maulvi, F. A., & Desai, D. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820779-6.00009-8 · Cited by 9
Systems Biology: Its past, present and potential
Mendoza, E. (2009) · SciEnggJ · doi:10.54645/xzup10231 · Cited by 9
Biological Complexity and the Need for Computational Approaches
Kitano, H. (2016) · History, philosophy and theory of the life sciences · doi:10.1007/978-3-319-47000-9_16 · Cited by 9
Self-citationIdentification of Minimum Set of Master Regulatory Genes in Gene Regulatory Networks
Bakhteh, S., Ghaffari-Hadigheh, A., & Chaparzadeh, N. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2875692 · Cited by 9
“Proper analyzing of these networks facilitate solving many different biological and medical issues such as drug design and diagnosis of the various diseases [34].”
BackgroundAdimy, M., Bernard, S., Clairambault, J., Crauste, F., Génieys, S., & Pujo-Menjouet, L. (2008) · HAL · doi:10.1684/hma.2008.0282 · Cited by 9
“Kitano a montré [46, 47] comment en biologie des systèmes des notions de robustesse et de fragilité pouvaient être utiles pour décrire le métabolisme cellulaire et pour aider à la conception de nouveaux médicaments.”
BackgroundAn Integrative Thrombosis Network: Visualization and Topological Analysis
Kong, X., Zhou, W., Wan, J., Zhang, Q., Ni, J., & Yuanjia, H. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/265303 · Cited by 9
Zhu, W., Qiu, X., Xu, X., & Lu, C. (2010) · Science China Chemistry · doi:10.1007/s11426-010-4082-0 · Cited by 9
Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity
Li, X., Ke, Z., Lian, D., Yuan, J., & Pan, Y. (2020) · Inflammation Research · doi:10.1007/s00011-020-01336-y · Cited by 9
Scientific Challenges in Systems Biology
Kitano, H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-531-2_1 · Cited by 9
“How we can systematically identify such strategic therapy is yet unknown, and will be a subject of major research in the future ( 49 ).”
BackgroundSelf-citationWeinstein, N., Carlsen, J., Schulz, S., Stapleton, T., Henriksen, H., Travnik, E., & Johansson, P. I. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1341145 · Cited by 8
Bayesian Computation Methods for Inferring Regulatory Network Models Using Biomedical Data
Tian, T. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1503-8_12 · Cited by 8
Modern cancer drug discovery: integrating targets, technologies and treatments
Workman, P., & Collins, I. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50004-5 · Cited by 8
A systematic study of chemogenomics of carbohydrates
Gu, J., Luo, F., Chen, L., Yuan, G., & Xu, X. (2014) · Molecular BioSystems · doi:10.1039/c3mb70534j · Cited by 8
Functional and systems biology approaches to Huntington's disease
Gonzalez-Couto, E. (2011) · Briefings in Functional Genomics · doi:10.1093/bfgp/elr003 · Cited by 8
Network models in drug discovery and regenerative medicine
Winkler, D. A. (2008) · Biotechnology annual review · doi:10.1016/s1387-2656(08)00005-7 · Cited by 8
“Very recently, there has been a paradigm shift in thinking in pharmaceutical research toward network ideas [16,18].”
BackgroundA Modularity-Based Method Reveals Mixed Modules from Chemical-Gene Heterogeneous Network
Song, J., Tang, S., Liu, X., Gao, Y., Yang, H., & Lu, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125585 · Cited by 8
“However, the increasing amount of constituents and associated targets leads to unprecedented complexity in the pharmacology research and drug design of multicomponent therapies [6].”
Strategies to optimize the use of targeted agents for tumor therapy
Becker, J. C., Ugurel, S., & Schrama, D. (2008) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2008.06496.x · Cited by 8
Robustness and Resilience of Dynamical Networks in Biology and Epidemiology
Proverbio, D., Katz, R., & Giordano, G. (2025) · Foundations and Trends® in Systems and Control · doi:10.1561/2600000036 · Cited by 7
Niss, K., Gómez‐Casado, C., Hjaltelin, J. X., Joeris, T., Agace, W. W., Belling, K., & Brunak, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107763 · Cited by 7
“When such areas of the matrix were graph-visualized (Figure 2G), the sub-structures turned out to be a topological motif called a bow-tie, which connected the protein complexes (Broder et al., 2000; Csete and Doyle, 2004; Kitano, 2004, 2007; Tieri et al., 2010).”
BackgroundComplex diseases demand novel treatment strategies: understanding drug combination
Siqueira, R., Fernandes, V., Ferreira, L., de Caro, V., Glaser, T., Ulrich, H., & Lameu, C. (2022) · Drug Combination Therapy · doi:10.53388/dct2022006 · Cited by 7
Traditional Chinese Medicine Active Ingredient-Metal Based Anticancer Agents
Chen, Z., Liang, H., & Liu, Y. (2012) · InTech eBooks · doi:10.5772/29125 · Cited by 7
“TCM possess multi-component, multi-target and co-regulatory features which meet the view points of multi-target drugs through the network approach (Csermely et al., 2005) and robustness-based approach to systems-oriented drug design (Kitano, 2007).”
BackgroundConvergent Evolution of Medicines
De, K., Li, X., & Zhang, H. (2008) · ChemMedChem · doi:10.1002/cmdc.200800093 · Cited by 7
Nøhr‐Nielsen, A., Bruin, M. L. D., Thomsen, M. S., Pipper, C. B., Lange, T., Bjerrum, O. J., & Lund, T. M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13986 · Cited by 7
“ble for the disease has been essential in driving the development of combination therapies, which are capable of targeting these complex networks at multiple sites simultaneously.(3) This is in particular the case for the treatment of infectious diseases e.”
BackgroundProtein-protein interactions: analysis and prediction
Frishman, D., Albrecht, M., Blankenburg, H., Bork, P., Harrington, E. D., Hermjakob, H., Jensen, L. J., Juan, D., Lengauer, T., Pagel, P., et al. (2008) · Springer eBooks · doi:10.1007/978-3-211-75123-7_17 · Cited by 7
“Apart from that, it is remarkable that some potential drugs have been found to be less effective than expected due to the intrinsic robustness of living systems against perturbations of molecular interactions (Kitano 2007) .”
Li, H., Ung, C. Y., Xiao, H., Liu, X. H., Li, B. W., Low, B. C., & Chen, Y. (2009) · Cancer · doi:10.1002/cncr.24485 · Cited by 7
Lee, S. Y., Sohn, S. B., Kim, H. U., Park, J. M., Kim, T. Y., Orth, J. D., & Palsson, B. Ø. (2012) · Springer eBooks · doi:10.1007/978-94-007-4534-6_1 · Cited by 6
“Robustness analysis of metabolism identifies these fragile points, but also identifies possible alternate routes the organism can use to counteract treatments that are suggested [50, 51].”
BackgroundAksam, V. K. M., Chandrasekaran, V. M., & Pandurangan, S. (2017) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2017.08.006 · Cited by 7
Nakao, A., Hu, A., Yamaguchi, T., Tabuchi, M., Ikarashi, Y., & Kobayashi, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4139812 · Cited by 6
“(e administration of such medicines is in accordance with a previous theory of multicomponent drugs [44].”
BackgroundWhat is Next for Small-Molecule Drug Discovery?
Doweyko, A. M., & Doweyko, L. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.72 · Cited by 6
Predicting effective drug combinations via network propagation
Ligeti, B., Alvarez, R. V., Lukacs, G., Győrffy, B., & Pongor, S. (2013) · IEEE Biomedical Circuits and Systems Conference (BioCAS) · doi:10.1109/biocas.2013.6679718 · Cited by 6
Tasaki, K. M. (2012) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2012.09.005 · Cited by 6
Jeong, E., Lim, Y., Kim, K. J., Ki, H., Lee, D., Suh, J., So, S.-H., Kwon, O., & Kim, J. Y. (2020) · Molecules · doi:10.3390/molecules25081967 · Cited by 6
“However, numerous disease states can only be explained by complex, multimolecular interactions rather than by the alteration of a single gene, gene product, or metabolite [20].”
BackgroundComputer-Aided Drug Design for Cancer Therapy
Daina, A., Röhrig, U. F., & Zoete, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11670-8 · Cited by 5
Salekeen, R., Mou, S. N., Islam, M. E., Ahmed, A., Billah, M. M., Rahman, S. M. M., & Islam, K. M. D. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1855248 · Cited by 5
“Systematic multiple target optimal intervention (MTOI) is an emerging field in cheminformatics and pharmacological research, which addresses these issues by studying drug-like molecules at the disease network levels (Csermely et al., 2005; Kitano, 2007; Zimmermann et al., 2007).”
BackgroundRafiev, A., Yakovlev, A., Tarawneh, G., Naylor, M. F., Moore, S. W., Thomas, D. B., Bragg, G. M., Vousden, M. L., & Brown, A. D. (2022) · IET Computers & Digital Techniques · doi:10.1049/cdt2.12041 · Cited by 5
Wang, P., Hao, D.-L., & Xiong, X. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117121 · Cited by 5
Talevi, A., & Bellera, C. L. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2373165 · Cited by 5
“Second, it has been suggested that the reductionist approach is insufficient to effectively address the treatment of complex diseases like epilepsy [24]; as asserted by Kitano [159], ‘complexity has to be controlled by complexity.’”
Network Medicine: New Paradigm in the -Omics Era
Guo, N. L. (2011) · Anatomy & Physiology · doi:10.4172/2161-0940.1000e106 · Cited by 5
Computational Methods for Multi-Target Drug Designing Against Mycobacterium tuberculosis
Srivastava, G., Tiwari, A., & Sharma, A. K. (2018) · Methods in pharmacology and toxicology · doi:10.1007/7653_2018_19 · Cited by 5
Gupta, V., Crudu, A., Matsuoka, Y., Ghosh, S., Rozot, R., Marat, X., Jäger, S., Kitano, H., & Breton, L. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0119-y · Cited by 5
Self-citationZhang, T., Zhang, Z., Dong, K., Li, G., & Zhu, H. Y. (2012) · PubMed Central · doi:10.3969/j.issn.1673-5374.2012.24.001 · Cited by 5
“The mechanisms of action of Chinese medicines involve multiple factors, which is consistent to a certain degree with multiple target therapy, and Chinese medicine has been a focus for drug development for complex diseases [5] .”
BackgroundAlloza, E., Al‐Shahrour, F., Cigudosa, J. C., & Dopazo, J. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-37 · Cited by 5
“Also, drug discovery processes need to account for this new scenario [38, 39].”
BackgroundpathPSA: A Dynamical Pathway-Based Parametric Sensitivity Analysis
Perumal, T. M., & Gunawan, R. (2014) · Industrial & Engineering Chemistry Research · doi:10.1021/ie403277d · Cited by 5
Application of Tracer-Based Metabolomics and Flux Analysis in Targeted Cancer Drug Design
Cascante, M., Selivanov, V. A., & Ramos‐Montoya, A. (2012) · Methods in pharmacology and toxicology · doi:10.1007/978-1-61779-618-0_10 · Cited by 5
Hai, C.-M. (2008) · Current Drug Discovery Technologies · doi:10.2174/157016308786733582 · Cited by 5
P2X7 receptors as targets for neuroprotection
Maneu, V., & García, A. G. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110877 · Cited by 4
Pharmacodynamics simulation of HOEC by a computational model of arachidonic acid metabolic network
Yang, W. J., Wang, X., Li, K., Liu, Y., Li, H., Wang, R., & Li, H. (2018) · Quantitative Biology · doi:10.1007/s40484-018-0163-4 · Cited by 4
“The intrinsic robustness of living systems against various perturbations is a key factor that target-oriented drug did not work as expected and even had inevitable side effects [22].”
BackgroundStrategies for Expanding Access and Improving the Quality of Pharmaceutical Services
Dias-Souza, M. V. (2016) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-4666-9961-8.ch008 · Cited by 4
Funabashi, M. (2015) · American Journal of Bioscience and Bioengineering · doi:10.11648/j.bio.20150306.17 · Cited by 4
“Especially phytochemicals are the source of most pharmaceutical products [14], and are candidates for long-tail drug discovery that is expected to be more compatible to the whole functioning of cellular metabolism than target-specific drugs [15].”
BackgroundSystems and Control Theory for Medical Systems Biology
Wellstead, P. E., Sreenath, S. N., & Cho, K. (2009) · IGI Global eBooks · doi:10.4018/978-1-60566-076-9.ch002 · Cited by 4
“Kitano, H. (2007). A robustness-based approach to systems-oriented drug design.”
BackgroundKamal, Ä., Nekkanti, S., Shankaraiah, N., & Sathish, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_27 · Cited by 4
‐Omics and Clinical Data Integration
Sanctis, G. D., Colombo, R., Damiani, C., Sacco, E., & Vanoni, M. (2018) · Wiley eBooks · doi:10.1002/9781119183952.ch15 · Cited by 4
Cavaliere, M., Mazza, T., & Sedwards, S. (2013) · Emergence, complexity and computation · doi:10.1007/978-3-319-03191-0_2 · Cited by 4
“be helpful to individuate the appropriate time-dependent dosage of antagonists in cancer treatments [39].”
BackgroundFuturistic Smart Architecture for a Rapid Disaster Response
Chikumbo, O., Lewis, S., Canard, H., & Norris, T. (2014) · Lecture notes in social networks · doi:10.1007/978-3-319-08819-8_3 · Cited by 4
What to expect from rational drug design
Adam, M. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.773 · Cited by 4
“Still, the proposals make it clear that drug discovery based on cell or whole organism systems would include both novel empirical methods, such as screening in cell-systems assays, and new aspects of theoretical modelling of systems [4,6] .”
BackgroundTummala, H., Goltsov, A., Khalil, H. S., Sproul, A. M., Scott, F. E., Mitev, V., & Zhelev, N. (2012) · Biodiscovery · doi:10.7750/biodiscovery.2012.6.4 · Cited by 4
“computational models of these pathways are considered promising tools in cancer research for prediction of cancer disease progression, development of biomarkers, and drug therapy efficacy [79-82].”
BackgroundInfluential[Drug targets discovery based on dynamic signal transduction networks].
Wang, J., & Li, X.-J. (2010) · PubMed · Cited by 4
de Diego, A. M. G., Lorrio, S., Hernández-Guijo, J. M., Gandía, L., & de Diego, A. M. G. (2012) · Wiley eBooks · doi:10.1002/9781118185537.ch4 · Cited by 4
Language and hardware acceleration backend for graph processing
Mokhov, A., de Gennaro, A., Tarawneh, G., Wray, J., Lukyanov, G., Mileiko, S., Scott, J., Yakovlev, A., & Brown, A. D. (2017) · Forum on specification and Design Languages · doi:10.1109/fdl.2017.8303899 · Cited by 4
Borisy, A. A., Zimmermann, G. R., & Lehár, J. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch15 · Cited by 4
Eckert, G. P., Song, Z., & Cheng, S. (2019) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2019.05.002 · Cited by 4
An approach to the conditional robustness problem for biochemical networks
Bianconi, F., Baldelli, E., & Valigi, P. (2014) · Proceedings of the ... American Control Conference/Proceedings of the American Control Conference · doi:10.1109/acc.2014.6859085 · Cited by 3
“Systems Biology models and robustness analysis have great potential in drug development, as suggested in [5], [6].”
BackgroundXiong, J., Rayner, S., Liang, F., & Li, Y. (2012) · Springer eBooks · doi:10.1007/978-94-007-4819-4_14 · Cited by 3
Multi-Level Complexities in Technological Development: Competing Strategies for Drug Discovery
Adam, M. (2010) · Boston studies in the philosophy of science · doi:10.1007/978-90-481-9051-5_5 · Cited by 3
“As shown above, the systems biologists have described the problem in terms of reduction and emergence (see, e.g., Kitano, 2007, 202; Butcher, 2005, 465; Horrobin, 2003, 153; van der Greef and McBurney, 2005, 961; Kubinyi, 2003, 665; Van Regenmortel, 2004).”
BackgroundInfluentialMolecular Network Analysis of Multiple Sclerosis Brain Lesion Proteome
Satoh, J. (2010) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.33.182 · Cited by 3
Kaur, M., & Silakari, O. (2016) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2016.1209555 · Cited by 3
Big Tumorigenesis Mechanisms in Systems Cancer Biology via Big Database Mining and Network Modeling
Chen, B., & Li, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809479-2.00009-3 · Cited by 3
EFFICACY AND SAFETY OF BAN HUANG ORAL LIQUID FOR TREATING BOVINE RESPIRATORY DISEASES
Li, B., Zhou, X., Niu, J.-R., Wei, X., Li, J., Yang, Y., Liu, X., Cheng, F., & Zhang, J. (2017) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcam.v14i2.6 · Cited by 3
“TCM uses a combination of active components to reach this goal (Kitano, 2007), triggering the immune system and enhancing immunity (Huo and Li, 2002; Shen et al., 2004; Zhang et al., 1998), and thus preventing and treating disease.”
BackgroundWray, J., & Whitmore, A. V. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_7 · Cited by 3
Future Outlook for Systems Biology
Young, D. L., & Michelson, S. (2011) · Wiley eBooks · doi:10.1002/9781118016435.ch14 · Cited by 3
REACH, animal testing, and the precautionary principle
Menache, A., & Nastrucci, C. (2012) · Medicolegal and Bioethics · doi:10.2147/mb.s33044 · Cited by 3
“Another essential property of complex biological systems is their robustness.(81,82) Robust systems are resistant to changes in the environment because they can adapt and have redundant components, which can act as a backup if individual components fail.”
From mouse genetics to systems biology
Balling, R. (2007) · Mammalian Genome · doi:10.1007/s00335-007-9044-2 · Cited by 3
Zheng, C., Qiu, M., Xu, X., Ye, H., Zhang, Q. Y., Li, Y., Liu, X., & Chen, J. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3329 · Cited by 3
“Considering complex diseases, the model of drug discovery has been changed from identifying a single target to identifying multi-targets based on systems biology (34).”
BackgroundCancer drug target identification and node-level analysis of the network of MAPK pathways
Aksam, V. K. M., Chandrasekaran, V. M., & Pandurangan, S. (2018) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-018-0165-1 · Cited by 3
Advances in Computational Systems Biology
Lodhi, H. M. (2010) · Wiley eBooks · doi:10.1002/9780470556757.ch1 · Cited by 3
“Effective systems based drug design techniques can be developed by exploiting the knowledge of the robustness of biological systems [ 57 ].”
BackgroundEffective Models of Periodically Driven Networks
Shulman, J., Seemann, L., & Gunaratne, G. H. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.10.008 · Cited by 3
“Adding to the difficulty of therapeutic intervention is the robustness of the solutions of most networks (2).”
BackgroundBioinformatics: Applications and Implications
Kasemsap, K. (2017) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-5225-2607-0.ch002 · Cited by 3
Cancer Robustness and Therapy Strategies
Kitano, H. (2011) · Springer eBooks · doi:10.1007/978-94-007-1567-7_17 · Cited by 3
“The important targets, the so-called hubs, need to be avoided as far as possible, with the synergy effect being applied to targets that are not thought to be important, but exist abundantly in the long tail of the distribution of the number of interactions of proteins and genes ( Kitano 2007 ).”
InfluentialSelf-citationComputational Modeling And Simulation Of Thrombus Formation
Luan, D. (2009) · eCommons (Cornell University) · Cited by 3
AI-driven Automated Discovery Tools Reveal Diverse Behavioral Competencies of Biological NetworksPreprint
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2024) · eLife · doi:10.7554/elife.92683.2 · Cited by 3
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.